Showing results (71-80 of 93) with videos related to
Sort By:
Pageof 10
Annals of the Rheumatic Diseases|January 20, 2022
Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritisMarc Corbera-Bellalta, Roser Alba-Rovira, Sujatha Muralidharan, et al.European Heart Journal|August 30, 2011
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairmentKeith A A Fox, Jonathan P Piccini, Daniel Wojdyla, et al.Annals of the Rheumatic Diseases|March 10, 2022
Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trialMaria C Cid, Sebastian H Unizony, Daniel Blockmans, et al.American Heart Journal|May 13, 2015
The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) studyG Kees Hovingh, Loek P Smits, Claudia Stefanutti, et al.European Heart Journal. Imaging Methods and Practice|July 24, 2024
Pericardial late gadolinium enhancement and time to recurrence: a substudy from RHAPSODY, a phase 3 clinical trial of rilonacept in recurrent pericarditisPaul C Cremer, David Lin, Sushil A Luis, et al.Journal of the American Heart Association|March 12, 2024
Sustained Pericarditis Recurrence Risk Reduction With Long-Term RilonaceptMassimo Imazio, Allan L Klein, Antonio Brucato, et al.International Journal of Immunopathology and Pharmacology|March 27, 2003
A seroepidemiological study of toxoplasma gondii infection in children of northern GreeceS Frydas, Y Theodoridis, T Rallis, et al.European Heart Journal|May 1, 2014
Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trialJean-Claude Tardif, Christie M Ballantyne, Philip Barter, et al.Circulation|June 5, 2014
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)Jonathan L Halperin, Graeme J Hankey, Daniel M Wojdyla, et al.Journal of the American Heart Association|October 17, 2022
Interleukin-1 Trap Rilonacept Improved Health-Related Quality of Life and Sleep in Patients With Recurrent Pericarditis: Results From the Phase 3 Clinical Trial RHAPSODYAntonio Brucato, Michelle Z Lim-Watson, Allan Klein, et al.Pageof 10